Price$3.00-0.04 (-1.15%)
05:30 PM07:45 PM
News · 26 weeks21+50%
2025-12-142026-06-07
Mix1190d
- SEC Filings7(64%)
- Other3(27%)
- Dividends1(9%)
Latest news
25 items- PRExicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-QREDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026. The delay was primarily due to additional time required following changes in the Company's financial reporting personnel and related filing procedures. The Company filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 w
- SECExicure Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - EXICURE, INC. (0001698530) (Filer)
- SECSEC Form 10-Q filed by Exicure Inc.10-Q - EXICURE, INC. (0001698530) (Filer)
- SECSEC Form NT 10-Q filed by Exicure Inc.NT 10-Q - EXICURE, INC. (0001698530) (Filer)
- PRExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors. Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and r
- SECExicure Inc. filed SEC Form 8-K: Leadership Update8-K - EXICURE, INC. (0001698530) (Filer)
- SECExicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EXICURE, INC. (0001698530) (Filer)
- SECExicure Inc. filed SEC Form 8-K: Leadership Update8-K - EXICURE, INC. (0001698530) (Filer)
- SECSEC Form 10-K filed by Exicure Inc.10-K - EXICURE, INC. (0001698530) (Filer)
- SECExicure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - EXICURE, INC. (0001698530) (Filer)
- PRExicure, Inc. Reports Full Year 2025 Financial ResultsREDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye
- INSIDERChief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 3% to 301 units (SEC Form 4)4 - EXICURE, INC. (0001698530) (Issuer)
- SECExicure Inc. filed SEC Form 8-K: Leadership Update8-K - EXICURE, INC. (0001698530) (Filer)
- SECExicure Inc. filed SEC Form 8-K: Leadership Update8-K - EXICURE, INC. (0001698530) (Filer)
- PRExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantREDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating burixafor (GPC-100/TG-0054), a highly selective CXCR4 inhibitor, in the journal Annals of Hematology. The manuscript, titled "Burixafor, a CXCR4 Inhibitor with a Differentiated Kinetics Profile: Results of a Phase 2 Study for Rapid Cell Mobilization in Multiple Myeloma and Lymphoma Patients Undergoing Transplant," reports results from a 12-participant, multi-center, open-label Phase 2 study (NCT02104427) evaluating burixafor in c
- SECExicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EXICURE, INC. (0001698530) (Filer)
- INSIDERLarge owner Exicure Hitron Inc. sold $1,162,652 worth of shares (258,367 units at $4.50), decreasing direct ownership by 14% to 1,598,947 units (SEC Form 4)4 - EXICURE, INC. (0001698530) (Issuer)
- PRExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem MeetingsREDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), taking place February 4-7, 2026, in Salt Lake City, UT. The presentation will serve as an encore of data reported previously, highlighting results from Exicure's open-label, multicenter Phase 2 trial (NCT05561751) evaluating burixafor in patient
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Exicure Inc.SCHEDULE 13D/A - EXICURE, INC. (0001698530) (Subject)
- INSIDERLarge owner Exicure Hitron Inc. sold $3,306,362 worth of Common (734,747 units at $4.50), decreasing direct ownership by 28% to 1,857,314 units (SEC Form 4)4 - EXICURE, INC. (0001698530) (Issuer)
- INSIDERLarge owner Exicure Hitron Inc. sold $3,335,724 worth of Common (741,272 units at $4.50), decreasing direct ownership by 22% to 2,592,061 units (SEC Form 4)4 - EXICURE, INC. (0001698530) (Issuer)
- INSIDERLarge owner Sangsangin Investment & Securities Co., Ltd. sold $3,774,322 worth of shares (433,332 units at $8.71), closing all direct ownership in the company (SEC Form 4)4 - EXICURE, INC. (0001698530) (Issuer)
- PRExicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual MeetingREDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPCs) in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). The data, which showed that approximately 90% of study participants achieved the primary endpoint, were presented today in an oral session at the 67th American Society of Hematology (A
- INSIDERChief Accounting Officer Miller Josh covered exercise/tax liability with 7 shares, decreasing direct ownership by 2% to 309 units (SEC Form 4)4 - EXICURE, INC. (0001698530) (Issuer)
- SECExicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EXICURE, INC. (0001698530) (Filer)
XCUR FAQ
6 questionsWhat does Exicure Inc. do?
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and...Where does XCUR stock trade?
Exicure Inc. (XCUR) is listed on NASDAQ.What sector and industry is XCUR in?
Exicure Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about XCUR?
Exicure Inc. has had 2 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Neutral with a $40.00 price target on 2021-12-13.What companies are similar to XCUR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare XCUR side-by-side with any of them on Quantisnow.How can I track XCUR on Quantisnow?
Quantisnow aggregates Exicure Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XCUR to receive live email and push alerts on every new disclosure.